Dataset Information

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).

ABSTRACT: To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes.A total of 75 patients with glycated haemoglobin (HbA1c) concentrations of ?7.5 to ?10.5% (?58 to ?91?mmol/mol) were randomized to receive once-daily empagliflozin 2.5?mg, empagliflozin 10?mg, empagliflozin 25?mg, or placebo as adjunct to insulin for 28?days. Insulin dose was to be kept as stable as possible for 7?days then adjusted, at the investigator's discretion, to achieve optimum glycaemic control. The primary exploratory endpoint was change from baseline in 24-h urinary glucose excretion (UGE) on day?7.Empagliflozin significantly increased 24-h UGE versus placebo on days?7 and 28. On day?28, adjusted mean differences with empagliflozin versus placebo in changes from baseline in: HbA1c were -0.35 to -0.49% (-3.8 to -5.4?mmol/mol; all p?

SUBMITTER: Pieber TR

PROVIDER: S-EPMC4745028 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).

Pieber T R TR Famulla S S Eilbracht J J Cescutti J J Soleymanlou N N Johansen O E OE Woerle H J HJ Broedl U C UC Kaspers S S

Diabetes, obesity & metabolism 20150624 10

<h4>Aims</h4>To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes.<h4>Methods</h4>A total of 75 patients with glycated haemoglobin (HbA1c) concentrations of ≥7.5 to ≤10.5% (≥58 to ≤91 mmol/mol) were randomized to receive once-daily empagliflozin 2.5 mg, empagliflozin 10 mg, empagliflozin 25 mg, or placebo as adjunct to insulin for 28 days. Insulin dose was to be kept as stable as possible for 7 days then adjusted, at the ...[more]

PMID: 26080652

Similar Datasets

Project description:BACKGROUND:This study evaluated the effect of empagliflozin on postprandial glucose (PPG) and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus (T2DM). METHODS:Patients (N?=?60; baseline mean [SD] HbA1c 7.91 [0.80]%; body mass index 24.3 [3.2] kg/m(2)) were randomized to receive empagliflozin 10 mg (n?=?20), empagliflozin 25 mg (n?=?19) or placebo (n?=?21) once daily as monotherapy for 28 days. A meal tolerance test and continuous glucose monitoring (CGM) for 24 hours were performed at baseline and on days 1 and 28. The primary endpoint was change from baseline in area under the glucose concentration-time curve 3 hours after breakfast (AUC1-4h for PPG) at day 28. RESULTS:Adjusted mean (95%) differences versus placebo in changes from baseline in AUC1-4h for PPG at day 1 were -97.1 (-126.5, -67.8) mg?·?h/dl with empagliflozin 10 mg and -91.6 (-120.4, -62.8) mg?·?h/dl with empagliflozin 25 mg (both p?<?0.001 versus placebo) and at day 28 were -85.5 (-126.0, -45.0) mg?·?h/dl with empagliflozin 10 mg and -104.9 (-144.8, -65.0) mg?·?h/dl with empagliflozin 25 mg (both p?<?0.001 versus placebo). Adjusted mean (95% CI) differences versus placebo in change from baseline in 24-hour mean glucose (CGM) at day 1 were -20.8 (-27.0, -14.7) mg/dl with empagliflozin 10 mg and -23.9 (-30.0, -17.9) mg/dl with empagliflozin 25 mg (both p?<?0.001 versus placebo) and at day 28 were -24.5 (-35.4, -13.6) mg/dl with empagliflozin 10 mg and -31.7 (-42.5,-20.9) mg/dl with empagliflozin 25 mg (both p?<?0.001 versus placebo). Changes from baseline in mean amplitude of glucose excursions (MAGE; CGM) were not significantly different with either empagliflozin dose versus placebo at either timepoint. Curves of mean glucose (CGM) did not change between baseline and day 1 or 28 with placebo, but shifted downward with empagliflozin. Percentage of time with glucose ?70 to <180 mg/dl increased from 52.0% at baseline to 77.0% at day 28 with empagliflozin 10 mg and from 55.0% to 81.1% with empagliflozin 25 mg, without increasing time spent with hypoglycemia. CONCLUSION:Empagliflozin for 28 days reduced PPG from the first day and improved daily blood glucose control in Japanese patients with T2DM. TRIAL REGISTRATION:Clinicaltrials.gov NCT01947855.

Dataset Information

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).

Publications

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure